Pherecydes

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023

Retrieved on: 
Friday, June 23, 2023
Shareholder, Bank statement, ADS, Public, Policy, Element, Delegation, Mergers and acquisitions, ISIN, Phage therapy, Combined, Therapy, Security (finance), Holding company, Pherecydes, Euronext Paris, Euronext

The merger between Erytech and Pherecydes has been approved by the Combined General Meeting on the basis of an exchange ratio of 4 Pherecydes shares for 15 Erytech shares (the "Merger") which gave full powers to Erytech's Board of Directors to record the definitive completion of the Merger.

Key Points: 
  • The merger between Erytech and Pherecydes has been approved by the Combined General Meeting on the basis of an exchange ratio of 4 Pherecydes shares for 15 Erytech shares (the "Merger") which gave full powers to Erytech's Board of Directors to record the definitive completion of the Merger.
  • Erytech shareholders also approved the change of Erytech's corporate name to "Phaxiam Therapeutics".
  • At the Pherecydes Combined General Meeting held today at 1pm, after the Erytech Combined General Meeting, all the resolutions supported by the Pherecydes Board of Directors were approved, including those relating to the Merger.
  • The Erytech Board of Directors met after the Pherecydes Combined General Meeting and acknowledged the completion of the Merger.

ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit

Retrieved on: 
Tuesday, June 20, 2023
AMF, Annual general meeting, Euronext Paris, United Nations Security Council Resolution 29, Mass meeting, Failure, Commercial code, Partner, Pherecydes, Hearing

Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP) announces the filing of a new lawsuit by Akkadian Partners.

Key Points: 
  • Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP) announces the filing of a new lawsuit by Akkadian Partners.
  • Despite the rejection by the President of the Lyon Commercial Court of Akkadian Partners' request to postpone the General Meeting's vote on the proposed merger, Akkadian has initiated new legal proceedings with the clear aim of continuing its attempt to destabilize Erytech.
  • As part of this new procedure, the first hearing of which will take place after the vote on the merger, Akkadian Partners is requesting the cancellation of the capital increase of May 15, 2023.
  • Erytech is confident of the outcome of this unfounded procedure, which appears bound to failure.

ERYTECH Responds to Akkadian’s Disinformation

Retrieved on: 
Monday, June 12, 2023
Exercise, Pancreatic cancer, Compagnie Nationale du Rhône, Uncertainty, Communication, Commercial Court, Employment, Annual general meeting, Drug development, Interview, Assembly, ALL, Chapter 11, Title 11, United States Code, Partner, Annual, Abergel, Commissaire, Sale, LOI, Proposed merger of Publicis and Omnicom, Documentation, Acquisition, Risk, CEST, Seriousness, Phage therapy, Knowledge, Infection, AMF, Fraud, Catalent, General assembly, Risk management, Management, Pharmaceutical industry, Cryptocurrency, Pherecydes, Court

Cambridge, MA (U.S.) and Lyon (France), June 12, 2023, 7:00 am CEST – ERYTECH Pharma (Nasdaq & Euronext: ERYP), today reacts to a series of disinformation attempts by Akkadian Partners to try and destabilize ERYTECH.

Key Points: 
  • Cambridge, MA (U.S.) and Lyon (France), June 12, 2023, 7:00 am CEST – ERYTECH Pharma (Nasdaq & Euronext: ERYP), today reacts to a series of disinformation attempts by Akkadian Partners to try and destabilize ERYTECH.
  • The proposed transaction is structured as a merger of PHERECYDES into ERYTECH, pursuant to which PHERECYDES shareholders will receive 15 new ERYTECH shares for every 4 PHERECYDES shares they own.
  • On 13 April, Akkadian Partners, an entity domiciled in Luxembourg, crossed the threshold of 5% of the share capital of ERYTECH Pharma.
  • Finally, it is important to note that a failure of the merger would only lead to the destruction of value for ERYTECH and its shareholders.

ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes

Retrieved on: 
Monday, June 5, 2023
Annual, Partner, Pherecydes, Annual general meeting

Akkadian's legal action against ERYTECH aims to obtain the adjournment of the vote on certain resolutions at the Annual General Meeting scheduled for June 23, 2023, so that ERYTECH shareholders will not be able to vote on the merger with Pherecydes.

Key Points: 
  • Akkadian's legal action against ERYTECH aims to obtain the adjournment of the vote on certain resolutions at the Annual General Meeting scheduled for June 23, 2023, so that ERYTECH shareholders will not be able to vote on the merger with Pherecydes.
  • Akkadian is also requesting the appointment of a legal expert to review the terms of the merger.
  • To the best of ERYTECH's knowledge, Akkadian held 1,850,000 ERYTECH shares on May 24, 2023, representing around 5% of the company's share capital.
  • ERYTECH intends to obtain the dismissal of this legal action, which it considers unfounded, and thus enable its shareholders to vote on the merger with Pherecydes on June 23.

ERYTECH Provides Business and Financial Update for the First Quarter of 2023

Retrieved on: 
Tuesday, May 9, 2023
Uncertainty, Pherecydes, Partner, Infection, AMR, President's Management Advisory Board, Acquisition, Management, Phage therapy, General assembly, Fine chemical, Pharmaceutical industry, Security (finance), Cryptocurrency, Clothing

Lyon (France) and Cambridge (MA, US), May 9, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update for the first quarter of 2023.

Key Points: 
  • Lyon (France) and Cambridge (MA, US), May 9, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update for the first quarter of 2023.
  • This transaction is the result of the extensive strategic review process announced by ERYTECH on several occasions since November 2021.
  • Note that ERYTECH is not aware of any further acquisitions of ERYTECH shares completed by Akkadian.
  • As of March 31, 2023, ERYTECH had cash and cash equivalents totaling €30.5 million (approximately $33.7 million), compared with €38.8 million as of December 31, 2022.

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022

Retrieved on: 
Wednesday, March 22, 2023
Pancreatic cancer, ALL, Pherecydes, EGM, Infection, Sale, Seminal vesicles, Patient, Phage therapy, Catalent, FDA, BLA, Pharmaceutical industry, TNBC

Cambridge, MA (U.S.) and Lyon (France), March 22, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update for the fourth quarter and full year of 2022.

Key Points: 
  • Cambridge, MA (U.S.) and Lyon (France), March 22, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update for the fourth quarter and full year of 2022.
  • We sold our US manufacturing site, sharply reduced our cash burn, focused on our most promising preclinical programs, and relentlessly pursued partnering options”, said Gil Beyen, Chief Executive Officer of ERYTECH.
  • Linked to the halt of the Company’s lead program Graspa®, a restructuring program was initiated in May 2022.
  • Key financial figures for the twelve months of 2022 compared with the same period of the previous year are summarized below:

Pherecydes Pharma Announces Its Intention to List on the Euronext Growth® Market in Paris

Retrieved on: 
Tuesday, January 5, 2021
Health, Infectious diseases, Research, Pharmaceutical, Science, Biotechnology, Microbiology, Medical specialties, Bacteriology, Bacteriophages, Bacteriophage, Biology, Phage therapy, Pherecydes, Staphylococcus aureus

Pherecydes Pharma (Pherecydes or company), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announced its intention to list on the Euronext Growth market in Paris.

Key Points: 
  • Pherecydes Pharma (Pherecydes or company), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announced its intention to list on the Euronext Growth market in Paris.
  • Pherecydes Pharma is developing a portfolio of phages, natural bacteria-killing viruses, targeting 3 of the most resistant and dangerous bacteria, including Staphylococcus aureus.
  • Copies of the Document dInformation is available free of charge from Pherecydes Pharma, and on the websites of Pherecydes Pharma ( www.pherecydes-pharma.com ) and Euronext ( www.euronext.com ).
  • Pherecydes Pharma is not contemplating registering an offer or any public offering of securities, in the United States of America.